Metastatic lymph node ratio in stage III rectal cancer; prognostic significance in addition to the 7th edition of the TNM classification

European Journal of Surgical Oncology

Volumn 36, Issue 12, 2010, Pages 1180-1186

  Dekker, J W T ^a   Peeters, K C ^a   Putter, H ^a   Vahrmeijer, A L ^a   Van De Velde, C J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cut off values; Lymph node ratio; Lymph node yield; Prognosis; Rectal cancer

Indexed keywords

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RISK ASSESSMENT; AGED; ANALYSIS OF VARIANCE; CANCER STAGING; CLINICAL TRIAL; EPIDEMIOLOGY; KAPLAN MEIER METHOD; LYMPH NODE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RECTUM TUMOR; RISK; RISK FACTOR; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 79952065694     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.09.007     Document Type: Article

References (43)

1. Kapiteijn E, Putter H, van de Velde CJ. Impact of the Introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in the Netherlands. Br J Surg 2002;89(9):1142-9. (Pubitemid 34989221)
2. den DM, Krijnen P, Marijnen CA, et al. Improved overall survival for patients with rectal cancer since 1990: the effects of TME surgery and pre-operative radiotherapy. Eur J Cancer 2008;44(12):1710-6.
3. Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg 1990;211(2):187-95. (Pubitemid 20063206)
4. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001;358(9290):1291-304.
5. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351 (17):1731-40.
6. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but No survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246(5):693-701. (Pubitemid 350035641)
7. Taal BG, van TH, Zoetmulder FA. Adjuvant 5FU Plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001;85(10):1437-43. (Pubitemid 34001570)
8. Glimelius B, Dahl O, Cedermark B, et al. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the nordic gastrointestinal tumour adjuvant therapy group. Acta Oncol 2005;44 (8):904-12. (Pubitemid 41780118)
9. Dahl O, Fluge O, Carlsen E, et al. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian gastrointestinal cancer group. Acta Oncol 2009;48(3):368-76.
10. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355(11):1114-23. (Pubitemid 44394918)
11. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJQuasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370(9604):2020-9.
12. Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S. Adjuvant chemotherapy with Uracil-Tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 2006;36(4):237-44.
13. Collette L, Bosset JF, den DM, et al. Patients with curative resection of CT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant Fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment Of Cancer Radiation Oncology Group. J Clin Oncol 2007;25(28):4379-86.
14. Valentini V, Aristei C, Glimelius B, et al. Multidisciplinary rectal cancer management: 2nd European rectal cancer consensus conference (EURECA-CC2). Radiother Oncol 2009;92(2):148-63.
15. Sobin LH, Wittekind CH. UICC (2002) TNM Classification of malignant tumours. 6th ed. New York: Wiley & Sons; 2002. Ref Type: Generic.
16. Sobin LH, Gospodarowicz MK, Wittekind CH. UICC (2009) TNM Classification of malignant tumours. 7th ed. New York: Wiley & Sons; 2009. Ref Type: Generic.
17. Quirke P, Williams GT, Ectors N, Ensari A, Piard F, Nagtegaal I. The future of the TNM staging system in colorectal cancer: time for a debate? Lancet Oncol 2007;8(7):651-7. (Pubitemid 46995637)
18. Shariat SF, Capitanio U, Jeldres C, Karakiewicz PI. Can nomograms be superior to other prediction tools? BJU Int 2009;103(4):492-5.
19. Bando E, Yonemura Y, Taniguchi K, Fushida S, Fujimura T, Miwa K. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol 2002;9(8):775-84.
20. Voordeckers M, Vinh-Hung V, Van De Steene J, Lamote J, Storme G. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 2004;70(3):225-30. (Pubitemid 38520153)
21. Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003;169(3):943-5. (Pubitemid 36188130)
22. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004;70 (3):235-40.
23. Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23(34):8706-12. (Pubitemid 46211514)
24. Derwinger K, Carlsson G, Gustavsson B. A study of lymph node ratio as a prognostic Marker in colon cancer. Eur J Surg Oncol 2008;34(7): 771-5.
25. Lee HY, Choi HJ, Park KJ, et al. Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma. Ann Surg Oncol 2007;14(5):1712-7.
26. Schumacher P, Dineen S, Barnett Jr C, Fleming J, Anthony T. The metastatic lymph node ratio predicts survival in colon cancer. Am J Surg 2007;194(6):827-31.
27. Thorn CC, Woodcock NP, Scott N, Verbeke C, Scott SB, Ambrose NS. What factors affect lymph node yield in surgery for rectal cancer? Colorectal Dis 2004;6(5):356-61. (Pubitemid 39236535)
28. Mekenkamp LJ, van Krieken JH, Marijnen CA, van de Velde CJ, Nagtegaal ID. Lymph node retrieval in rectal cancer is dependent on many factorsethe role of the tumor, the patient, the surgeon, the radiotherapist, and the pathologist. Am J Surg Pathol 2009;33(10):1547-53.
29. Morcos B, Baker B, Al MM, Haddad H, Hashem S. Lymph node yield in rectal cancer surgery: effect of preoperative chemoradiotherapy. Eur J Surg Oncol 2010;36(4):345-9.
30. Kapiteijn E, Kranenbarg EK, Steup WH, et al. Total Mesorectal Excision (TME) with or without preoperative radiotherapy in the treatment of Primary rectal cancer. prospective randomised trial with standard operative and histopathological techniques. Dutch ColoRectal cancer group. Eur J Surg 1999;165(5):410-20. (Pubitemid 29377119)
31. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345(9):638-46.
32. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007;26(11):2389-430. (Pubitemid 46730255)
33. Altman DG, Lausen B, SauerbreiW, Schumacher M. Dangers of using "Optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86(11):829-35. (Pubitemid 2100935)
34. Stocchi L, Nelson H, Sargent DJ, et al. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol 2001;19(18):3895-902. (Pubitemid 32880068)
35. Peng J, Xu Y, Guan Z, et al. Prognostic significance of the metastatic lymph node ratio in node-positive rectal cancer. Ann Surg Oncol 2008; 15(11):3118-23.
36. Kim YS, Kim JH, Yoon SM, et al. Lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;74(3):796-802.
37. Moug SJ, Saldanha JD, McGregor JR, Balsitis M, Diament RH. Positive lymph node retrieval ratio optimises patient staging in colorectal cancer. Br J Cancer 2009;100(10):1530-3.
38. Marijnen CA, Nagtegaal ID, Klein KE, et al. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001;19(7):1976-84. (Pubitemid 32702542)
39. Dane F, Ozturk MA, Turhal S. Adequacy of lymph node dissection should be taken into consideration while determining the prognostic significance of the lymph node ratio: in regard to Kim et Al. (Int J Radiat Oncol Biol Phys 2009;74:796-802). Int J Radiat Oncol Biol Phys 2009;75(5):1625.
40. Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001;19(1):157-63. (Pubitemid 32063492)
41. Derwinger K, Carlsson G, Gustavsson B. Stage migration in colorectal cancer related to improved lymph node assessment. Eur J Surg Oncol 2007;33(7):849-53. (Pubitemid 47279054)
42. Inoue K, Nakane Y, Iiyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 2002;9 (1):27-34. (Pubitemid 34262894)
43. Marijnen CA, Nagtegaal ID, Kapiteijn E, et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003;55(5):1311-20. (Pubitemid 36338299)